The RxEd Podcast

What to say when a GLP-1 patient walks up to the counter. Titration expectations, managing GI side effects before they derail therapy, injection technique, missed doses, and the honest conversation about what happens when treatment stops.

Trafficking victims come through pharmacy doors, and almost no one recognizes them. This course covers the legal definitions, the myths that block identification, the physical, behavioral, environmental, and prescription-pattern red flags, the PEARR framework for approaching someone safely, and the reporting obligations that differ for minors and adults. Includes three vignettes with embedded discussion questions.

A reject code tells you which field or rule the plan objected to — but not whether it's yours to fix. This episode covers how claim adjudication works, what M/I codes mean, and which of the common NCPDP rejects point to correctable claim data versus a coverage rule needing payer or prescriber action. Including why "refill too soon" often traces back to the last fill.

Why does a gut hormone quiet appetite in the brain? A short tour of GLP-1 physiology — where it's secreted, what DPP-4 does to it, how the drug versions escape that fate, and where the receptors that drive satiety actually live.

Most medication errors don't start at the counter — they start at the keyboard. This episode walks through the data entry screen from the top: patient identifiers and why you never edit a DOB to clear a reject, allergies and drug–disease interactions, look-alike drug names, high-alert strengths, and the prescriber fields everyone skips. Plus the five-category checklist to run before you hit enter.

Kratom and 7-OH aren't the same thing — and the DEA's action only targets one of them. This episode unpacks the July 2026 notices of intent to temporarily place concentrated 7-hydroxymitragynine and three synthetic analogues into Schedule I, why the 0.05% threshold matters, what's left untouched, and where the federal timeline actually stands. Plus the state-level patchwork that's already in effect regardless of what DEA does.

The technician's role in immunization changed fast — six states permitted technician vaccinators in 2020, and 47 plus DC did by 2025. This episode covers what drove that shift, the PREP Act authority now extended through 2029, the APhA/WSU training and PTCB certificate paths, and the operational work technicians run even where they don't administer. Plus why state rules, not federal, govern your practice.

Flu, COVID, and RSV in one sitting — here's the 2026–2027 lineup. New flu strains across the board, an updated COVID formula, and RSV recommendations that now reach down to age 50 for high-risk adults. A quick map of who's eligible for what heading into respiratory season.

Five minutes, one season's worth of changes. All three strains in the 2026–2027 flu vaccine were updated from last season — new H1N1, H3N2, and B/Victoria components — after a rough year for vaccine match. We cover what's actually different in this year's formulation, and then the part that never changes: the same handful of counseling questions patients ask at the counter every single fall, and how to answer them fast.

For the first time, an mRNA cancer therapy has succeeded in a Phase 3 trial. Merck and Moderna's intismeran autogene — a vaccine built from a patient's own tumor mutations — improved recurrence-free and distant metastasis-free survival when added to Keytruda in high-risk melanoma. We look at why this result is being called a landmark, touch on how mRNA teaches the immune system to hunt cancer cells, and what comes next.